J. Greg Davis Appointed President & Chief Executive Officer of Tryton Medical, Inc.
Mr. Davis joins Tryton Medical after a successful 20-year career withGuidant and Eli Lilly & Company. Mr. Davis is an experienced medical deviceexecutive with broad global and functional experience in finance,manufacturing, sales and general management. Most recently he was president ofGuidant, Japan with profit and loss responsibility for the company's $225million cardiovascular business. Prior to his work in Japan, Mr. Davis managedGuidant's product portfolio in 13 Asian countries. Mr. Davis earned a BS inMechanical Engineering from The University of Minnesota and an MBA from TheUniversity of Michigan.
"I am excited about this opportunity because I believe the TrytonSide-Branch Stent(TM) will redefine the standard of care for bifurcationlesions," said Mr. Davis. "Tryton's elegant design, ease-of-use and stellarclinical results are impressive. I look forward to implementing the company'saggressive European commercialization strategy and U.S. clinical trial plans."
"We are delighted to welcome Greg to Tryton Medical during this pivotaltime in the company's development," said Dan Cole, Co-Founder and Board Memberof Tryton and General Partner of Spray Venture Partners. "We believe hisproven track record of growing successful businesses and achieving resultswill enable Tryton to capitalize on its leadership position in the industry."
"Greg's rich international experience and customer focus will be realassets as we launch the Side-Branch Stent(TM) across Europe," said RickAnderson, Board Member of Tryton and Managing Director of PTV Sciences, andformer Company Group Chairman, Cordis Corporation. "The Tryton 1 (First inMan) trial results and recent CE Mark approval have created strong interestand enthusiasm among the European physician community."
About Tryton Medical, Inc.
Tryton Medical, Inc. was founded in 2003 by Aaron V. Kaplan, M.D.(Associate Professor of Medicine at Dartmouth Medical School/Dartmouth-Hitchcock Medical Center) and Dan Cole to develop stents for the definitivetreatment of bifurcation lesions. The company recently completed a $14 millionround of financing, led by PTV Sciences and RiverVest Venture Partners. TheCompany will be headquartered in Research Triangle Park, NC. For moreinformation on Tryton Medical contact J. Greg Davis, firstname.lastname@example.org or visit www.trytonmedical.com.
SOURCE Tryton Medical, Inc.
You May Also Like